       Document 0508
 DOCN  M9610508
 TI    Prospective study of antigenemia, plasma viremia and lymphocytic viremia
       in HIV-infected hemophiliacs.
 DT    9601
 AU    Melon Garcia S; de Ona Navarro M; Rodriguez Pinto C; Fernandez Urgelles
       M; Martinez Gutierrez A; de la Iglesia P; Mendez Garcia FJ; Microbiology
       Service, Hospital Central de Asturias, Oviedo,; Spain.
 SO    Eur J Clin Microbiol Infect Dis. 1995 May;14(5):400-5. Unique Identifier
       : AIDSLINE MED/96039816
 AB    A total of 186 blood samples from 24 HIV-1 seropositive hemophiliac
       patients, monitored every four months for 29 months, were investigated
       for the presence of viral antigen in plasma. In addition, peripheral
       blood mononuclear cells (PBMC) were cultured for HIV-1, using normal
       PBMC as a target for replication. Antigenemia was detected in 51% of the
       patients and from PBMC in 87.5% of the patients. The incidence of HIV
       isolation in asymptomatic patients (42.8%) was similar to that found in
       symptomatic patients (51.4%). Patients with opportunistic infections had
       a higher incidence of lymphocytic viremia (p < 0.05). Plasma viremia was
       closely associated (p < 0.05) with low CD4+ counts and infection
       progression. The persistence of antigenemia was also a marker of a poor
       clinical course. In treated patients, plasma viremia was the marker that
       better correlated with the clinical course, and it did not appear during
       the first nine months of therapy. Zidovudine doses of > 500 mg/day
       significantly lowered the appearance of antigenemia and lymphocytic
       viremia (p < 0.05).
 DE    Adolescence  Adult  Biological Markers/BLOOD
       Hemophilia/*COMPLICATIONS/IMMUNOLOGY  Human  HIV Antigens/*BLOOD  HIV
       Infections/*COMPLICATIONS/DRUG THERAPY/IMMUNOLOGY
       HIV-1/IMMUNOLOGY/*ISOLATION & PURIF  Leukocytes,
       Mononuclear/IMMUNOLOGY/VIROLOGY  Lymphocytes/IMMUNOLOGY/VIROLOGY
       Prognosis  Prospective Studies  Support, Non-U.S. Gov't
       Viremia/*COMPLICATIONS/IMMUNOLOGY  Zidovudine/THERAPEUTIC USE  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

